Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afrezza PK/PD Variability in T1DM
NCT02485327Phase 1Completed
- Sponsor
- MannKind
- Start
- Jul 2015
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TI-Inhalation Powder B in type 1 diabetes mellitus (T1D), sponsored by MannKind. Primary endpoints: Area under the serum insulin concentration time curve from time 0 to 8H and Area under the glucose infusion rate curve necessary to maintain euglycemia at 8 hours. Started Jul 2015; status: completed.
02
Drugs
TI-Inhalation Powder B
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02485327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485327.